Biomarkers for osteoarthritis: Current position and steps towards further validation

被引：158

作者：

Hunter, David J. ^{[1
,2
]}

Nevitt, Michael ^{[3
]}

Losina, Elena ^{[4
,5
]}

Kraus, Virginia ^{[6
]}

机构：

[1] Univ Sydney, Royal N Shore Hosp, Dept Rheumatol, Reserve Rd, Sydney, NSW 2065, Australia

[2] Univ Sydney, Northern Clin Sch, Kolling Inst, Sydney, NSW 2065, Australia

[3] Univ Calif San Francisco, OAI Coordinating Ctr, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA

[4] Brigham & Womens Hosp, Orthopaed & Arthritis Ctr Outcomes Res, Dept Orthoped Surg, Boston, MA 02115 USA

[5] Harvard Univ, Sch Med, Boston, MA USA

[6] Duke Univ, Dept Med, Durham, NC USA

来源：

BEST PRACTICE & RESEARCH IN CLINICAL RHEUMATOLOGY | 2014年 / 28卷 / 01期

基金：

澳大利亚研究理事会;

关键词：

Osteoarthritis; Biomarkers; SURROGATE END-POINTS; JOINT SPACE WIDTH; KNEE OSTEOARTHRITIS; DRUG DEVELOPMENT; RECOMMENDATIONS; RESPONSIVENESS; QUALIFICATION; REPLACEMENT; RELIABILITY; TRIALS;

D O I：

10.1016/j.berh.2014.01.007

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Historically disease knowledge development and treatment innovation in osteoarthritis (OA) has been considered to be slow. One of the many reasons purported as responsible for this slow pace has been the alleged lack of valid and responsive biomarkers to ascertain efficacy, which itself has been dependent upon the slow evolution of the understanding of the complex nature of joint tissue biology. This narrative review outlines the rationale for why we need OA biomarkers with regard to biomarker validation and qualification. The main biomarkers in current development for OA are biochemical and imaging markers. We describe an approach to biomarker validation and qualification for OA clinical trials that has recently commenced with the Foundation of NIH OA Biomarkers Consortium study cosponsored by the Osteoarthritis Research Society International (OARSI). With this approach we endeavor to identify, develop, and qualify biological markers (biomarkers) to support new drug development, preventive medicine, and medical diagnostics for osteoarthritis. (C) 2014 Elsevier Ltd. All rights reserved.

引用

页码：61 / 71

页数：11

共 39 条

[1]

Access Economics Pty Ltd for Arthritis Australia, 2007, PAINF REAL EC IMP AR

[2] The Vioxx debacle [J].

Alpert, JS .

AMERICAN JOURNAL OF MEDICINE, 2005, 118 (03) :203-204

[3] The biomarkers consortium: On the critical path of drug discovery [J].

Altar, C. A. .

CLINICAL PHARMACOLOGY & THERAPEUTICS, 2008, 83 (02) :361-364

[4]

[Anonymous], 2012, NAT MOST COMM CAUS D

[5]

[Anonymous], ARTHRITIS CARE RES H

[6]

[Anonymous], 2001, MMWR-MORBID MORTAL W, V50, P149

[7]

Arthritis prevalence and activity limitations-United States, 1990, MMWR-MORBID MORTAL W, V43, P433

[8] Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework [J].

Atkinson, AJ ;

Colburn, WA ;

DeGruttola, VG ;

DeMets, DL ;

Downing, GJ ;

Hoth, DF ;

Oates, JA ;

Peck, CC ;

Schooley, RT ;

Spilker, BA ;

Woodcock, J ;

Zeger, SL .

CLINICAL PHARMACOLOGY & THERAPEUTICS, 2001, 69 (03) :89-95

[9] Classification of osteoarthritis biomarkers:: a proposed approach [J].

Bauer, D. C. ;

Hunter, D. J. ;

Abramson, S. B. ;

Attur, M. ;

Corr, M. ;

Felson, D. ;

Heinegard, D. ;

Jordan, J. M. ;

Kepler, T. B. ;

Lane, N. E. ;

Saxne, T. ;

Tyree, B. ;

Kraus, V. B. .

OSTEOARTHRITIS AND CARTILAGE, 2006, 14 (08) :723-727

[10]

Berndt E, 2006, OPPORTUNITIES IMPROV

← 1 2 3 4 →